PSPedro Sánchez-Rovira

Pedro Sánchez-Rovira

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Pedro Sánchez-Rovira has a total of 412 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Autophagy-Related Genetic Variants Influence Prostate Cancer Susceptibility and Are Associated with Immune and Inflammatory Phenotypes

    by José Antonio López-López, Antonio José Cabrera-Serrano, María Carretero-Fernández, Rob ter Horst, Fernando Jesús Reyes-Zurita, Carmen González-Olmedo, Francisco José García-Verdejo, Juan Francisco Gutiérrez-Bautista, María Inmaculada Bravo-Fernández, Jesús Olivares-Ruiz, et al.

    Background: Autophagy maintains cellular homeostasis and has context-dependent roles in prostate cancer (PCa). We investigated whether common variation in autophagy-related genes influences PCa susceptibility. Methods: We meta-analyzed UK Biobank and FinnGen genome-wide association study (GWAS) datasets, including 17,583 cases and 279,188 controls. Among 50,020 shared variants, 16 were prioritized, and 13 were evaluated in a Spanish cohort (218 cases and 468 controls). Functional analyses were conducted in two Human Functional Genomics Project (HFGP) cohorts (500FG and 300OB) and complemented by in silico molecular quantitative trait locus (QTL) analyses. Results: In the overall meta-analysis, TNFSF10-rs7631904 showed the strongest association (OR = 1.07, P = 4.92×10-7). ARNT-rs72992015 was associated with PCa risk in Spain (OR = 2.09, P = 5.55×10-3) and overall (OR = 1.07, P = 2.80×10-6), with between-cohort heterogeneity (Phet = 0.01). ARNT-rs72992015 was associated with circulating VEGF concentrations in healthy participants (P = 7.86×10-4) and TNFSF10-rs7631904 was associated with the monocyte-to-lymphocyte ratio (P = 8.81×10-4), circulating EN-RAGE (P = 2.85×10-3), and cathepsin L concentrations (P = 8.34×10-3) in obese participants. Prostate eQTL analyses linked VAMP3, ARNT and MAP1LC3A variants to VAMP3, CTSS and MAP1LC3A expression, respectively. Conclusions: These findings identify autophagy-related susceptibility signals with exploratory immune, inflammatory, and regulatory associations. Genetic replication, colocalization analyses, and experimental validation are needed to establish their functional relevance.

  • Open Access

    Effectiveness of a Music Therapy Intervention in Cancer Patients Under Active Treatment at the University Hospital of Jaén: A Non-Randomized Controlled Trial

    by Belen Gutierrez-Sanchez, Jose Antonio Lopez-Lopez, Antonio Ochando-Garcia, Francisco Segura-Galan, Henrique Da-Silva-Domingues, Lucia Ortega-Donaire, Rocio Boyer-Posada, Pedro Sanchez-Rovira, Jose Gutierrez-Gascon, Rafael Del-Pino-Casado

    Introduction: The diagnosis and evolution of cancer generate a multidimensional impact (physical, psychological, emotional, social, and spiritual) on the patient. Some active treatments entail long stays in the day hospital, which can deteriorate patients' quality of life. Objective: To analyze the effectiveness of a live music session in cancer patients under active treatment. Specifically, its impact on anxiety, treatment-related symptoms, satisfaction, and perception of session duration was assessed. Method: A non-randomized controlled trial of two parallel arms with pre-post measurement was conducted in patients with active intravenous cancer treatment at the University Hospital of Jaén (n = 125; GI = 60; CG = 65). Results: The findings reflect that the intervention group significantly reduced the need for nursing care (OR = 0.89; 95% CI: 0.82 - 0.97) and perceived that the treatment proceeded faster (OR = 4.60; 95% CI: 1.80 - 11.79). Likewise, the assessment that the infusion was more enjoyable was significantly higher in the intervention group compared to the control group (3.78 ± 0.98 vs. 3.08 ± 0.71; p < 0.001). No significant differences in anxiety were achieved. Conclusion: A single live music session makes the treatment be perceived as shorter and more enjoyable; in addition to a favorable clinical trend toward better tolerance of cancer treatment.

  • Open Access

    Supplementary Data1 from Neoadjuvant Abemaciclib plus Letrozole Versus Chemotherapy in Patients with HR+/HER2− Highly Proliferative Breast Cancer

    by Miguel Martín, Ángel L. Guerrero-Zotano, María E. Pérez-López, Manuel Ruiz-Borrego, Noelia Martínez Jáñez, José I. Chacón, Miguel Gil-Gil, Raquel Andrés, Begoña Bermejo, Pedro Sánchez-Rovira, et al.

  • Open Access

    Neoadjuvant Abemaciclib plus Letrozole Versus Chemotherapy in Patients with HR+/HER2− Highly Proliferative Breast Cancer

    by Miguel Martín, Ángel L. Guerrero-Zotano, María E. Pérez-López, Manuel Ruiz-Borrego, Noelia Martínez Jáñez, José I. Chacón, Miguel Gil-Gil, Raquel Andrés, Begoña Bermejo, Pedro Sánchez-Rovira, et al.

    Purpose: Neoadjuvant chemotherapy is standard for high-risk hormone receptor–positive and human epidermal growth factor receptor 2–negative (HR+/HER2−) breast cancer. This study evaluates whether 12 months of letrozole plus abemaciclib could be an alternative. Patients and Methods: The phase II, open-label CARABELA trial randomized patients with HR+/HER2− stage II to III breast cancer with Ki-67 ≥20% to receive letrozole/abemaciclib for 12 months or chemotherapy for 6 months. Patients were stratified by menopausal status, tumor–node–metastasis, and Ki-67 index (<30% vs. ≥30%). The primary endpoint was the rate of residual cancer burden (RCB) 0 to I. Secondary endpoints included clinical response rate (CRR) and correlations of Ki-67 and recurrence score (RS) with tumor response. A Bayesian design aimed to assess treatment similarity. Results: A total of 200 patients (median age 53 years, 57% postmenopausal, 79% stage II, 77% Ki-67 ≥30%, 58% RS ≥26) were randomized. RCB 0 to I was achieved in 13% [letrozole/abemaciclib; 95% credible intervals (CrI), 7.4%–20.5%] versus 18% (chemotherapy; 95% CrI, 11.5%–26.4%), failing to show similarity between treatment arms. The CRR were 78% (letrozole/abemaciclib) versus 71% (chemotherapy; P = 0.26). Tumors with Ki-67 ≥30% and/or RS results ≥26 showed a trend toward higher RCB 0 to I rates with chemotherapy (23% vs. 17%; P = 0.52). RCB 0 to I rates were similar between treatments for tumors with Ki-67 <30% or RS <26. Conclusions: CARABELA trial results suggest that 12 months of letrozole/abemaciclib may not offer similar efficacy to that of chemotherapy in achieving RCB 0 to I. However, in less proliferative tumors (RS <26 or Ki-67 <30%), outcomes were comparable, suggesting that letrozole/abemaciclib could replace (neo)adjuvant chemotherapy in selected patients.


  • Open Access

    Crosstalk Between Autophagy and Oxidative Stress in Hematological Malignancies: Mechanisms, Implications, and Therapeutic Potential

    by Antonio José Cabrera-Serrano, José Manuel Sánchez-Maldonado, Carmen González-Olmedo, María Carretero-Fernández, Leticia Díaz-Beltrán, Juan Francisco Gutiérrez-Bautista, Francisco José García-Verdejo, Fernando Gálvez-Montosa, José Antonio López-López, Paloma García-Martín, et al.

    Autophagy is a fundamental cellular process that maintains homeostasis by degrading damaged components and regulating stress responses. It plays a crucial role in cancer biology, including tumor progression, metastasis, and therapeutic resistance. Oxidative stress, similarly, is key to maintaining cellular balance by regulating oxidants and antioxidants, with its disruption leading to molecular damage. The interplay between autophagy and oxidative stress is particularly significant, as reactive oxygen species (ROS) act as both inducers and by-products of autophagy. While autophagy can function as a tumor suppressor in early cancer stages, it often shifts to a pro-tumorigenic role in advanced disease, aiding cancer cell survival under adverse conditions such as hypoxia and nutrient deprivation. This dual role is mediated by several signaling pathways, including PI3K/AKT/mTOR, AMPK, and HIF-1α, which coordinate the balance between autophagic activity and ROS production. In this review, we explore the mechanisms by which autophagy and oxidative stress interact across different hematological malignancies. We discuss how oxidative stress triggers autophagy, creating a feedback loop that promotes tumor survival, and how autophagic dysregulation leads to increased ROS accumulation, exacerbating tumorigenesis. We also examine the therapeutic implications of targeting the autophagy-oxidative stress axis in cancer. Current strategies involve modulating autophagy through specific inhibitors, enhancing ROS levels with pro-oxidant compounds, and combining these approaches with conventional therapies to overcome drug resistance. Understanding the complex relationship between autophagy and oxidative stress provides critical insights into novel therapeutic strategies aimed at improving cancer treatment outcomes.


  • Open Access

    Assessment of Untargeted Metabolomics by Hydrophilic Interaction Liquid Chromatography−Mass Spectrometry to Define Breast Cancer Liquid Biopsy-Based Biomarkers in Plasma Samples

    by Carmen González Olmedo, Leticia Díaz Beltrán, Verónica Madrid García, José Luis Palacios Ferrer, Alicia Cano Jiménez, Rocío Urbano Cubero, José Pérez del Palacio, Caridad Díaz, Francisca Vicente, Pedro Sánchez Rovira

    An early diagnosis of cancer is fundamental not only in regard to reducing its mortality rate but also in terms of counteracting the progression of the tumor in the initial stages. Breast cancer (BC) is the most common tumor pathology in women and the second deathliest cancer worldwide, although its survival rate is increasing thanks to improvements in screening programs. However, the most common techniques to detect a breast tumor tend to be time-consuming, unspecific or invasive. Herein, the use of untargeted hydrophilic interaction liquid chromatography−mass spectrometry analysis appears as an analytical technique with potential use for the early detection of biomarkers in liquid biopsies from BC patients. In this research, plasma samples from 134 BC patients were compared with 136 from healthy controls (HC), and multivariate statistical analyses showed a clear separation between four BC phenotypes (LA, LB, HER2, and TN) and the HC group. As a result, we identified two candidate biomarkers that discriminated between the groups under study with a VIP > 1 and an AUC of 0.958. Thus, targeting the specific aberrant metabolic pathways in future studies may allow for better molecular stratification or early detection of the disease.


  • Open Access

    Real-world clinical scenarios during introduction of trastuzumab biosimilar for HER2-positive breast cancer in the European Union

    by Lucjan Wyrwicz, César A Rodríguez Sánchez, Pedro Sánchez-Rovira, Sandra Lewis, Darcie Sandschafer, Tevy San

    Aim: Trastuzumab-anns is an intravenously administered biosimilar to trastuzumab approved by the EMA and US FDA for treatment of HER2+ early and metastatic breast cancer as well as metastatic gastr... Plain language summary Some patients have a type of breast cancer caused by abnormal amounts of a normal growth factor receptor. This growth factor receptor, known as human epidermal growth factor ...


  • Open Access

    Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization

    by Esther Clavero, José Manuel Sanchez-Maldonado, Angelica Macauda, Rob Ter Horst, Belém Sampaio-Marques, Artur Jurczyszyn, Alyssa Clay-Gilmour, Angelika Stein, Michelle A. T. Hildebrandt, Niels Weinhold, et al.

    Multiple myeloma (MM) arises following malignant proliferation of plasma cells in the bone marrow, that secrete high amounts of specific monoclonal immunoglobulins or light chains, resulting in the massive production of unfolded or misfolded proteins. Autophagy can have a dual role in tumorigenesis, by eliminating these abnormal proteins to avoid cancer development, but also ensuring MM cell survival and promoting resistance to treatments. To date no studies have determined the impact of genetic variation in autophagy-related genes on MM risk. We performed meta-analysis of germline genetic data on 234 autophagy-related genes from three independent study populations including 13,387 subjects of European ancestry (6863 MM patients and 6524 controls) and examined correlations of statistically significant single nucleotide polymorphisms (SNPs; p < 1 × 10−9) with immune responses in whole blood, peripheral blood mononuclear cells (PBMCs), and monocyte-derived macrophages (MDM) from a large population of healthy donors from the Human Functional Genomic Project (HFGP). We identified SNPs in six loci, CD46, IKBKE, PARK2, ULK4, ATG5, and CDKN2A associated with MM risk (p = 4.47 × 10−4−5.79 × 10−14). Mechanistically, we found that the ULK4rs6599175 SNP correlated with circulating concentrations of vitamin D3 (p = 4.0 × 10−4), whereas the IKBKErs17433804 SNP correlated with the number of transitional CD24+CD38+ B cells (p = 4.8 × 10−4) and circulating serum concentrations of Monocyte Chemoattractant Protein (MCP)-2 (p = 3.6 × 10−4). We also found that the CD46rs1142469 SNP correlated with numbers of CD19+ B cells, CD19+CD3− B cells, CD5+IgD− cells, IgM− cells, IgD−IgM− cells, and CD4−CD8− PBMCs (p = 4.9 × 10−4−8.6 × 10−4) and circulating concentrations of interleukin (IL)-20 (p = 0.00082). Finally, we observed that the CDKN2Ars2811710 SNP correlated with levels of CD4+EMCD45RO+CD27− cells (p = 9.3 × 10−4). These results suggest that genetic variants within these six loci influence MM risk through the modulation of specific subsets of immune cells, as well as vitamin D3−, MCP-2−, and IL20-dependent pathways.


  • Open Access

    TFG-β Nuclear Staining as a Potential Relapse Risk Factor in Early-Stage Non-Small-Cell Lung Cancer

    by Nuria Cárdenas-Quesada, Leticia Díaz-Beltrán, Carmen Rosa-Garrido, Bélgica Márquez-Lobo, Adela Sabio-González, Rafael J. Luque-Barona, María Isabel Núñez, Pedro Sánchez-Rovira

    Nowadays, the impact of the tumor-immune microenvironment (TME) in non-small-cell lung cancer (NSCLC) prognosis and treatment response remains unclear. Thus, we evaluated the expression of PD-L1, tumor-infiltrating lymphocytes (TILs), and transforming growth factor beta (TGF-β) in NSCLC to identify differences in TME, detect possible new prognostic factors, and assess their relationship. We retrospectively analyzed 55 samples from patients who underwent NSCLC surgery and had over a 5-year follow-up. PD-L1 expression was determined by immunohistochemistry following standard techniques. The presence of TILs was evaluated at low magnification and classified into two categories, “intense” and “non-intense”. Cytoplasmic TGF-β staining visualization was divided into four categories, and unequivocal nuclear staining in >1% of viable tumor cells was defined as “present” or “absent”. Our aim was to identify differences in disease-free survival (DFS) and overall survival (OS). Tumor stage was the only objective prognostic factor for OS. PD-L1 expression and the presence of TILs had no prognostic impact, neither their combination. There seems to be a lower expression of PD-L1 and a higher expression of TILs in early stages of the disease. Our TGF-β nuclear staining analysis was promising, since it was associated with worse DFS, revealing this protein as a possible prognostic biomarker of recurrence for resectable NSCLC.


  • Open Access

    Hypoxia-Inducible Factor-1 Alpha Expression Is Predictive of Pathological Complete Response in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy

    by César L. Ramírez-Tortosa, Rubén Alonso-Calderón, José María Gálvez-Navas, Cristina Pérez-Ramírez, José Luis Quiles, Pedro Sánchez-Rovira, Alberto Jiménez-Morales, Mcarmen Ramírez-Tortosa

    To demonstrate the value of hypoxia-inducible factor-1α (HIF-1α) in predicting response in patients with breast cancer receiving standard neoadjuvant chemotherapy (NAC). Methods: Ninety-five women enrolled in two prospective studies underwent biopsies for the histopathological diagnosis of breast carcinoma before receiving NAC, based on anthracyclines and taxanes. For expression of HIF-1α, EGFR, pAKT and pMAPK, tumor samples were analyzed by immunohistochemistry in tissues microarrays. Standard statistical methods (Pearson chi-square test, Fisher exact test, Kruskal–Wallis test, Mann–Whitney test and Kaplan–Meier method) were used to study the association of HIF-1α with tumor response, survival and other clinicopathologic variables/biomarkers. Results: HIF-1α expression was positive in 35 (39.7%) cases and was significantly associated to complete pathological response (pCR) (p = 0.014). HIF-1α expression was correlated positively with tumor grade (p = 0.015) and Ki-67 expression (p = 0.001) and negativity with progesterone receptors (PR) (p = 0.04) and luminal A phenotype expression (p = 0.005). No correlation was found between HIF-1α expression and EGFR, pAKT and pMAPK. In terms of survival, HIF-1α expression was associated with a significantly shorter disease-free survival (p = 0.013), being identified as an independent prognostic factor in multivariate analysis. Conclusions: Overexpression of HIF-1α is a predictor of pCR and shorter DFS; it would be valuable to confirm these results in prospective studies.